TechConnect Innovator Spotlight:
|
Methods and products for reducing adhesions post surgery
The University of Adelaide, Adelaide, AU
TECH BRIEF
This technology proposes to repurpose a known iron chelating agent, for use in reducing risk of surgical adhesions without impacting wound healing properties.
TECHNOLOGY SUMMARY
Researchers at the University of Adelaide have identified a novel method to treat surgical adhesions, through the use of an iron chelation and/or antioxidant agent, in both in vitro and in vivo models. In vivo studies using a sheep laminectomy model show that the antioxidant iron chelator, Deferiprone, delivered by surgical hydrogel inhibits proliferation and migration of fibroblasts. The treatment appears to reduce all key characteristics of adhesions, including the strength, thickness, extent, severity and/or vascularisation. In addition, the chosen surgical hydrogel delivery system, provided maximum release of the agent to the surgical site within 48 hours. This is consistent with the critical period for blocking adhesion formation.
AREA/MATURITY/AWARDS
Primary Application Area: Biotech, Pharma, Medical Devices
Technology Development Status: Prototype
Technology Readiness Level: TRL 3
Vetted Programs/Awards: University of Adelaide Commercial Accelerator Scheme
CSIRO ON Prime program
SHOWCASE SUMMARY
Organization Type: Academic/Gov Lab
GOVT/EXTERNAL FUNDING SOURCES
External Funding to Date: The Hospital Research Foundation grant